Top Section/Ad
Top Section/Ad
Most recent
Calendar quirk could keep issuance going in December
◆ Praemia refis at a tighter coupon ◆ Schneider lands tight at the short end ◆ Minimal concessions needed
French biotech seeks to accelerate cancer vaccine program
◆ Single digit premiums offered ◆ Reverse Yankees dominating euro supply ◆ Floaters proving popular with multi-tranche issuers
More articles/Ad
More articles/Ad
More articles
-
Chinese policy banks and corporations are planning to sell renminbi bonds onshore to battle the coronavirus outbreak, using the capital markets as a source of key funding during a challenging time for the financial industry. -
Asia's dollar bond market reopened on Wednesday amid volatility around the rapid spread of the novel coronavirus. But debt bankers in the region are cautiously optimistic about the state of the market.
-
A fall in equity markets last week reflected an automatic reaction to the possibility of a new global pandemic. But the more substantial effect of the coronavirus outbreak on equities may be reflected in economic performance, rather than the rate of contagion.
-
The outbreak of the novel coronavirus in China is taking its toll on Asia's capital markets. Many countries have acted quickly to contain the disease as much as possible, leaving investors, bankers and companies with capital market ambitions in limbo, with many forced to cancel travel plans and work from home. The outbreak shows no signs of abating — but it may not mar the capital markets for long.
-
Chinese biotechnology firm Akesobio has resubmitted its IPO documents with the Hong Kong Stock Exchange, two months after the bourse rejected its original listing application.
-
Hong Kong’s stock exchange has returned Chinese biotechnology firm Akeso’s listing application, a deal being sponsored by JP Morgan and Morgan Stanley.
